ADMA Biologics Inc represents a strong commitment to developing and delivering innovative plasma-derived products for the treatment of immune deficiencies and other infectious diseases. The company's corporate philosophy centers around maximizing patient access to life-saving therapies, ensuring product quality and safety, and fostering a culture of excellence in research and development. ADMA Biologics Inc values integrity, collaboration, and dedication to improving patient outcomes. Through its cutting-edge technologies and strategic partnerships, the company strives to address unmet medical needs and make a positive impact on global healthcare. ADMA Biologics Inc is dedicated to providing high-quality products and delivering value to patients, healthcare professionals, and stakeholders.

ADMA Biologics Inc is primarily present in the United States.

ADMA Biologics Inc has achieved significant milestones in its journey. The company has successfully gained FDA approval for its first plasma-derived biologic, RI-002™. In addition, they have expanded their product portfolio by launching BIVIGAM®, a treatment for primary humoral immunodeficiency, and ASCENIV™, a hyperimmune globulin. ADMA Biologics Inc also received FDA approval for acquisition of their BOC facility in Boca Raton, Florida, which has resulted in increased plasma collection capacity. These milestones have strengthened ADMA Biologics Inc's position in the market and reflect their commitment to providing innovative solutions and expanding their reach in the biopharmaceutical industry.

ADMA Biologics Inc is a biopharmaceutical company specializing in the development and commercialization of plasma-derived products for the treatment of immune deficiencies and other infectious diseases. Founded in 2004, ADMA Biologics has evolved into a leading player in the immunoglobulin market. The company operates its own plasma collection centers and has a state-of-the-art fractionation facility located in Boca Raton, Florida. ADMA Biologics strives to deliver high-quality, plasma-derived products to patients with unmet medical needs. With a strong commitment to innovation and excellence, ADMA Biologics continues to expand its product pipeline and market presence, aiming to improve the lives of patients worldwide. Note: The provided answer is only for reference purposes and should be tailored or reviewed according to the specific requirements or guidelines provided by the professional stock website.

The main competitors of ADMA Biologics Inc in the market include companies such as Grifols, CSL Ltd, and Octapharma.

ADMA Biologics Inc is primarily active in the biopharmaceutical and healthcare industries.

ADMA Biologics Inc operates as a biopharmaceutical company. The company develops and produces specialty plasma-derived products for the treatment of immune deficiencies and infectious diseases. ADMA Biologics focuses on the production and marketing of its hyperimmune globulin products, which are used to treat various medical conditions. With its emphasis on specialty plasma-derived products, ADMA Biologics Inc aims to improve patient outcomes and address unmet medical needs.

ADMA Biologics KGV ir 35,36.

ADMA Biologics KUV ir 8,08.

AlleAktien kvalitātes vērtējums ADMA Biologics ir 4/10.

gaidāmā ADMA Biologics apgrozījums ir 364,65 milj. USD.

gaidāmā ADMA Biologics peļņa ir 83,35 milj. USD.

ADMA Biologics Inc is a US biopharmaceutical company focused on the development of intravenous immunoglobulins (IVIG). The company was founded in 2004 and is headquartered in Ramsey, New Jersey. ADMA Biologics Inc's business model is based on the production and marketing of IVIG products for the treatment of primary immune deficiency diseases (PID). The company is divided into three business segments: manufacturing, sales and marketing of IVIG products, pipeline product development, and management of licenses and patents. ADMA Biologics Inc currently produces two IVIG products: BIVIGAM and ASCENIV. BIVIGAM is used to treat primary immune deficiency diseases, while ASCENIV is administered through intravenous push-injection. ADMA Biologics Inc is also working on developing additional IVIG products, and holds licenses and patents in the field of plasma proteins and related technologies. In summary, ADMA Biologics Inc's business model revolves around the production and marketing of IVIG products for the treatment of primary immune deficiency diseases. The company is involved in manufacturing, sales, and marketing of these products, as well as the development of new pipeline products. They also hold licenses and patents in the field of plasma proteins and related technologies.

ADMA Biologics izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt ADMA Biologics vai uzņēmums nedod dividendes.

ADMA Biologics ISIN ir US0008991046.

ADMA Biologics WKN ir A12FAG.

ADMA Biologics simbols ir ADMA.

Pēdējo 12 mēnešu laikā ADMA Biologics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos ADMA Biologics plāno maksāt dividendes 0 USD apmērā.

ADMA Biologics pašreizējā dividendu rentabilitāte ir .

ADMA Biologics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

ADMA Biologics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

ADMA Biologics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu ADMA Biologics apmērā 0 USD, kas tika izmaksāta 28.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 28.07.2024..

Pēdējās dividendes izmaksa notika 28.07.2024..

Gadā 2023, ADMA Biologics izmaksāja 0 USD dividendes.

ADMA Biologics dividendes tiek izmaksātas USD.